Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 14/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888873 | 1.00 | HTR1A (0.46) | HTR1ASLC6A4CYP3A4CYP2C8DRD2 | |
| SCHEMBL4894800 | 0.98 | HTR1A (0.46) | HTR1ASLC6A4CYP3A4CYP2C8DRD2 | |
| SCHEMBL4898959 | 0.98 | HTR1A (0.46) | HTR1ASLC6A4CYP3A4CYP2C8DRD2 | |
| SCHEMBL4783791 | 0.95 | HTR1A (0.46) | HTR1ASLC6A4CYP3A4CYP2C8DRD2 | |
| SCHEMBL4782871 | 0.95 | HTR1A (0.46) | HTR1ASLC6A4CYP3A4CYP2C8DRD2 | |
| SCHEMBL4781236 | 0.93 | HTR1A (0.47) | HTR1ASLC6A4CYP3A4CYP2C8DRD2 | |
| SCHEMBL4781901 | 0.93 | HTR1A (0.47) | HTR1ASLC6A4CYP3A4CYP2C8DRD2 | |
| SCHEMBL4898253 | 0.87 | HTR1A (0.49) | HTR1ASLC6A4CYP3A4CYP2C8DRD2 | |
| SCHEMBL4898071 | 0.87 | HTR1A (0.49) | HTR1ASLC6A4CYP3A4CYP2C8DRD2 | |
| SCHEMBL4900902 | 0.87 | HTR1A (0.49) | HTR1ASLC6A4CYP3A4CYP2C8DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139546-A1 | Tetrahydroquinoline, indoline, and related aniline derivatives of heterocycle-fused benzodioxan methylamines | WYETH (US) | 2008-06-12 | — | — | US | claimed |
| US-20080139546-A1 | Tetrahydroquinoline, indoline, and related aniline derivatives of heterocycle-fused benzodioxan methylamines | WYETH (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139546-A1 | Tetrahydroquinoline, indoline, and related aniline derivatives of heterocycle-fused benzodioxan methylamines | HTR5A, HTR2C, HTR3A | HTR1A 6/4885SLC6A4 22/4885CYP3A4 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.